Photo od Ahmed Kotb
from daiichisankyo.us
Jun 22, 2025, 11:29
Ahmed Kotb: Choosing the Right DOAC For Your Patient?
Ahmed Kotb, Head of Global Oncology Medical Affairs at Daiichi Sankyo, shared on X:
“Choosing the right DOAC for your patient?
anticoagulant choice based on clinical profiles”
Elderly/Frail- Apixaban, Edoxaban
Obese -Apixaban or Rivaroxaban
CKD Apixaban, Edoxaban 30mg
GI Bleed Risk-Apixaban
Compliance issues- Edoxaban, Rivaroxaban
You can explore more detailed, evidence-based insights on individualized anticoagulant therapy at Hemostasis Today, your source for expert-guided approaches in thrombosis and hemostasis.
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda